Finally, we analyzed the expression of both TRIB2 and CEBPA in two human samples of SCLC prior to therapy, one resistant and one sensitive to frontline platinum-containing chemotherapy; we observed high expression of TRIB2 and low expression of CEBPA in the resistant tumor and the opposite in the sensitive. Here, TRIB2 is linked to neoplasm.